Zhang, Jq., Mao, Xm. & Zhou, Yp. Silybin decreases erythrocytic sorbitol level and improves peripheral nerve conduction velocity in patients with non-insulin dependent diabetes mellitus., CJIM 1, 84–86 (1995). https://doi.org/10.1007/BF02942753
Zhang Jia-qing, Mao Xiao-ming, Zhou Yun-ping. Silybin decreases erythrocytic sorbitol level and improves peripheral nerve conduction velocity in patients with non-insulin dependent diabetes mellitus. [J]. Chinese Journal of Integrative Medicine 1(2):84-86(1995)
Zhang, Jq., Mao, Xm. & Zhou, Yp. Silybin decreases erythrocytic sorbitol level and improves peripheral nerve conduction velocity in patients with non-insulin dependent diabetes mellitus., CJIM 1, 84–86 (1995). https://doi.org/10.1007/BF02942753DOI:
Zhang Jia-qing, Mao Xiao-ming, Zhou Yun-ping. Silybin decreases erythrocytic sorbitol level and improves peripheral nerve conduction velocity in patients with non-insulin dependent diabetes mellitus. [J]. Chinese Journal of Integrative Medicine 1(2):84-86(1995) DOI: 10.1007/BF02942753.
Silybin decreases erythrocytic sorbitol level and improves peripheral nerve conduction velocity in patients with non-insulin dependent diabetes mellitus
摘要
The effects of silybin on erythrocytic sorbitol level and peripheral nerve conduction velocity were studied in 14 cases of non-insulin dependent diabetes mellitus (NIDDM). After oral administration of silybin 231 mg/day for 4 weeks
no blood glucose change was observed in patients with NIDDM
while the erythrocytic sorbitol level was significantly decreased from 72.55±21.61 to 39.53±14.94 nmol/g · Hb (P<0.01). At the same time
peripheral nerve conduction velocity was also improved. These results indicate that silybin is an effective aldose reductase inhibitor which can improve the disorder of polyol pathway in NIDDM patients and prevent chronic complications of diabetes.
Abstract
The effects of silybin on erythrocytic sorbitol level and peripheral nerve conduction velocity were studied in 14 cases of non-insulin dependent diabetes mellitus (NIDDM). After oral administration of silybin 231 mg/day for 4 weeks
no blood glucose change was observed in patients with NIDDM
while the erythrocytic sorbitol level was significantly decreased from 72.55±21.61 to 39.53±14.94 nmol/g · Hb (P<0.01). At the same time
peripheral nerve conduction velocity was also improved. These results indicate that silybin is an effective aldose reductase inhibitor which can improve the disorder of polyol pathway in NIDDM patients and prevent chronic complications of diabetes.
关键词
Silybinsorbitolchronic complications of diabetesAldose Reductase Inhibitor
Keywords
Silybinsorbitolchronic complications of diabetesAldose Reductase Inhibitor
references
Greene DA. Sorbitol, phosphoinositides and sodiumpotassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987;316:599.
Malone JI, et al. Red cell sorbitol, an indicator of diabetic control. Diabetes 1980;29:861.
Sima AAF, et al. Regeneration and repair of myelinated fibers in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988;319:548.
Boulton AJM, et al. The efficacy and safety of the aldose reductase inhibitor tolrestat in the treatment of chronic sensori motor diabetic neuropathy. Diabetologia 1989;32:469A.